CLINICAL_TRIALS
trial_result
· 2015-04-16
Clinical Trial Update: Fulvestrant in Treating Patients With Recurrent Prostate Cancer [Phase 2]
Summary
A Phase 2 trial evaluating the estrogen receptor antagonist fulvestrant for recurrent prostate cancer was terminated; results were posted in 2015.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Roswell Park Cancer Institute | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2015-04-16